25 XP   0   0   10

Arcus Biosciences Inc
Buy, Hold or Sell?

Let's analyse Arcus Biosciences Inc together

PenkeI guess you are interested in Arcus Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Arcus Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Arcus Biosciences Inc

I send you an email if I find something interesting about Arcus Biosciences Inc.

Quick analysis of Arcus Biosciences Inc (30 sec.)










What can you expect buying and holding a share of Arcus Biosciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.08
Expected worth in 1 year
$2.94
How sure are you?
24.1%

+ What do you gain per year?

Total Gains per Share
$-2.15
Return On Investment
-14.6%

For what price can you sell your share?

Current Price per Share
$14.68
Expected price per share
$12.95 - $19.98
How sure are you?
50%

1. Valuation of Arcus Biosciences Inc (5 min.)




Live pricePrice per Share (EOD)

$14.68

Intrinsic Value Per Share

$-26.97 - $-32.20

Total Value Per Share

$-21.89 - $-27.12

2. Growth of Arcus Biosciences Inc (5 min.)




Is Arcus Biosciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$462m$724.9m-$187.9m-35.0%

How much money is Arcus Biosciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$76.7m-$64.9m-$11.8m-15.4%
Net Profit Margin-265.4%-5,054.2%--

How much money comes from the company's main activities?

3. Financial Health of Arcus Biosciences Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#121 / 1011

Most Revenue
#197 / 1011

Most Profit
#942 / 1011

Most Efficient
#665 / 1011

What can you expect buying and holding a share of Arcus Biosciences Inc? (5 min.)

Welcome investor! Arcus Biosciences Inc's management wants to use your money to grow the business. In return you get a share of Arcus Biosciences Inc.

What can you expect buying and holding a share of Arcus Biosciences Inc?

First you should know what it really means to hold a share of Arcus Biosciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Arcus Biosciences Inc is $14.68. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arcus Biosciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arcus Biosciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.08. Based on the TTM, the Book Value Change Per Share is $-0.54 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.51 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arcus Biosciences Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.89-6.1%-0.84-5.8%-0.73-5.0%-0.40-2.7%-0.32-2.2%
Usd Book Value Change Per Share-0.64-4.3%-0.54-3.7%-0.51-3.5%0.120.9%0.181.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.64-4.3%-0.54-3.7%-0.51-3.5%0.120.9%0.181.2%
Usd Price Per Share19.10-18.90-25.94-21.58-16.69-
Price to Earnings Ratio-5.36--5.61--8.83-2.57--1.57-
Price-to-Total Gains Ratio-29.92--37.18--51.15--36.60--43.43-
Price to Book Ratio3.76-3.23-3.24-4.24-3.58-
Price-to-Total Gains Ratio-29.92--37.18--51.15--36.60--43.43-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share14.68
Number of shares68
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.540.12
Usd Total Gains Per Share-0.540.12
Gains per Quarter (68 shares)-36.488.50
Gains per Year (68 shares)-145.9333.98
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-146-15603424
20-292-30206858
30-438-448010292
40-584-5940136126
50-730-7400170160
60-876-8860204194
70-1022-10320238228
80-1167-11780272262
90-1313-13240306296
100-1459-14700340330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%3.026.00.010.3%3.026.00.010.3%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%7.019.03.024.1%7.019.03.024.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%7.019.03.024.1%7.019.03.024.1%

Fundamentals of Arcus Biosciences Inc

About Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Fundamental data was last updated by Penke on 2024-04-04 23:33:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Arcus Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Arcus Biosciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Arcus Biosciences Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -261.3% means that $-2.61 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arcus Biosciences Inc:

  • The MRQ is -261.3%. The company is making a huge loss. -2
  • The TTM is -265.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-261.3%TTM-265.4%+4.2%
TTM-265.4%YOY-5,054.2%+4,788.8%
TTM-265.4%5Y-1,618.1%+1,352.7%
5Y-1,618.1%10Y-1,750.4%+132.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-261.3%-196.1%-65.2%
TTM-265.4%-211.9%-53.5%
YOY-5,054.2%-277.7%-4,776.5%
5Y-1,618.1%-432.9%-1,185.2%
10Y-1,750.4%-599.3%-1,151.1%
1.1.2. Return on Assets

Shows how efficient Arcus Biosciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arcus Biosciences Inc to the Biotechnology industry mean.
  • -7.4% Return on Assets means that Arcus Biosciences Inc generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arcus Biosciences Inc:

  • The MRQ is -7.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.4%TTM-6.5%-0.9%
TTM-6.5%YOY-4.5%-2.0%
TTM-6.5%5Y-6.0%-0.4%
5Y-6.0%10Y-6.8%+0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.4%-13.3%+5.9%
TTM-6.5%-12.7%+6.2%
YOY-4.5%-11.8%+7.3%
5Y-6.0%-14.0%+8.0%
10Y-6.8%-15.9%+9.1%
1.1.3. Return on Equity

Shows how efficient Arcus Biosciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arcus Biosciences Inc to the Biotechnology industry mean.
  • -17.5% Return on Equity means Arcus Biosciences Inc generated $-0.18 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arcus Biosciences Inc:

  • The MRQ is -17.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.5%TTM-14.4%-3.1%
TTM-14.4%YOY-9.0%-5.4%
TTM-14.4%5Y-9.2%-5.3%
5Y-9.2%10Y-9.3%+0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.5%-16.9%-0.6%
TTM-14.4%-16.0%+1.6%
YOY-9.0%-15.1%+6.1%
5Y-9.2%-19.7%+10.5%
10Y-9.3%-20.5%+11.2%

1.2. Operating Efficiency of Arcus Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Arcus Biosciences Inc is operating .

  • Measures how much profit Arcus Biosciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arcus Biosciences Inc to the Biotechnology industry mean.
  • An Operating Margin of -258.1% means the company generated $-2.58  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arcus Biosciences Inc:

  • The MRQ is -258.1%. The company is operating very inefficient. -2
  • The TTM is -278.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-258.1%TTM-278.5%+20.5%
TTM-278.5%YOY-5,571.7%+5,293.2%
TTM-278.5%5Y-1,739.6%+1,461.1%
5Y-1,739.6%10Y-1,848.2%+108.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-258.1%-290.9%+32.8%
TTM-278.5%-224.4%-54.1%
YOY-5,571.7%-288.3%-5,283.4%
5Y-1,739.6%-479.5%-1,260.1%
10Y-1,848.2%-625.2%-1,223.0%
1.2.2. Operating Ratio

Measures how efficient Arcus Biosciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4.10 means that the operating costs are $4.10 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arcus Biosciences Inc:

  • The MRQ is 4.097. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.073. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.097TTM4.073+0.024
TTM4.073YOY83.616-79.544
TTM4.0735Y25.454-21.381
5Y25.45410Y30.435-4.981
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0973.110+0.987
TTM4.0733.266+0.807
YOY83.6163.783+79.833
5Y25.4545.657+19.797
10Y30.4357.783+22.652

1.3. Liquidity of Arcus Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Arcus Biosciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.52 means the company has $4.52 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arcus Biosciences Inc:

  • The MRQ is 4.516. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.019. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.516TTM5.019-0.502
TTM5.019YOY6.767-1.748
TTM5.0195Y6.864-1.845
5Y6.86410Y8.156-1.292
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5163.905+0.611
TTM5.0194.212+0.807
YOY6.7675.337+1.430
5Y6.8646.062+0.802
10Y8.1566.401+1.755
1.3.2. Quick Ratio

Measures if Arcus Biosciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arcus Biosciences Inc to the Biotechnology industry mean.
  • A Quick Ratio of 7.79 means the company can pay off $7.79 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arcus Biosciences Inc:

  • The MRQ is 7.788. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.908. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.788TTM8.908-1.120
TTM8.908YOY11.447-2.539
TTM8.9085Y11.390-2.482
5Y11.39010Y12.216-0.826
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.7883.572+4.216
TTM8.9084.001+4.907
YOY11.4475.364+6.083
5Y11.3906.009+5.381
10Y12.2166.287+5.929

1.4. Solvency of Arcus Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Arcus Biosciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arcus Biosciences Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.58 means that Arcus Biosciences Inc assets are financed with 57.8% credit (debt) and the remaining percentage (100% - 57.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arcus Biosciences Inc:

  • The MRQ is 0.578. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.550. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.578TTM0.550+0.028
TTM0.550YOY0.497+0.053
TTM0.5505Y0.366+0.184
5Y0.36610Y0.291+0.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5780.336+0.242
TTM0.5500.334+0.216
YOY0.4970.271+0.226
5Y0.3660.3660.000
10Y0.2910.389-0.098
1.4.2. Debt to Equity Ratio

Measures if Arcus Biosciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arcus Biosciences Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 137.0% means that company has $1.37 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arcus Biosciences Inc:

  • The MRQ is 1.370. The company is able to pay all its debts with equity. +1
  • The TTM is 1.226. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.370TTM1.226+0.144
TTM1.226YOY0.989+0.238
TTM1.2265Y0.672+0.554
5Y0.67210Y0.508+0.164
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3700.382+0.988
TTM1.2260.397+0.829
YOY0.9890.341+0.648
5Y0.6720.432+0.240
10Y0.5080.465+0.043

2. Market Valuation of Arcus Biosciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Arcus Biosciences Inc generates.

  • Above 15 is considered overpriced but always compare Arcus Biosciences Inc to the Biotechnology industry mean.
  • A PE ratio of -5.36 means the investor is paying $-5.36 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arcus Biosciences Inc:

  • The EOD is -4.117. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.357. Based on the earnings, the company is expensive. -2
  • The TTM is -5.608. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.117MRQ-5.357+1.240
MRQ-5.357TTM-5.608+0.251
TTM-5.608YOY-8.825+3.218
TTM-5.6085Y2.567-8.175
5Y2.56710Y-1.568+4.135
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.117-2.262-1.855
MRQ-5.357-2.599-2.758
TTM-5.608-2.674-2.934
YOY-8.825-4.133-4.692
5Y2.567-6.258+8.825
10Y-1.568-6.171+4.603
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arcus Biosciences Inc:

  • The EOD is -3.548. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.616. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.436. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.548MRQ-4.616+1.068
MRQ-4.616TTM-5.436+0.821
TTM-5.436YOY-5.183-0.253
TTM-5.4365Y-9.222+3.786
5Y-9.22210Y-9.985+0.763
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.548-2.913-0.635
MRQ-4.616-3.275-1.341
TTM-5.436-3.508-1.928
YOY-5.183-5.620+0.437
5Y-9.222-8.306-0.916
10Y-9.985-8.854-1.131
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Arcus Biosciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.76 means the investor is paying $3.76 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arcus Biosciences Inc:

  • The EOD is 2.887. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.757. Based on the equity, the company is fair priced.
  • The TTM is 3.229. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.887MRQ3.757-0.869
MRQ3.757TTM3.229+0.528
TTM3.229YOY3.236-0.007
TTM3.2295Y4.243-1.014
5Y4.24310Y3.580+0.663
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.8871.858+1.029
MRQ3.7572.090+1.667
TTM3.2292.091+1.138
YOY3.2362.866+0.370
5Y4.2433.488+0.755
10Y3.5803.836-0.256
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Arcus Biosciences Inc.

3.1. Institutions holding Arcus Biosciences Inc

Institutions are holding 59.803% of the shares of Arcus Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc11.04410.0049100351704163434.3284
2023-12-31FMR Inc5.20420.00694728782-51270-1.0726
2023-12-31Vanguard Group Inc5.15130.00246807161868984.159
2023-12-31State Street Corporation4.66580.00394239577395530.9417
2023-09-30Octagon Capital Advisors LP2.16595.4272196800000
2023-12-31Ameriprise Financial Inc1.79920.00941634805548813.4736
2023-09-30Invus Financial Advisors, LLC1.774118.1364161207700
2023-12-31Boxer Capital LLC1.76331.5253160220000
2023-12-31Dimensional Fund Advisors, Inc.1.75490.0089159460915809411.0054
2023-09-30Partner Fund Management LP1.54631.1881140505600
2023-12-31AllianceBernstein L.P.1.30520.0087118594425136126.8955
2023-12-31Goldman Sachs Group Inc1.30370.0021184582596374101.3883
2023-12-31Geode Capital Management, LLC1.2570.00231142169645765.9926
2023-12-31Woodline Partners LP1.14160.2155103728200
2023-12-31Suvretta Capital Management, LLC1.05350.826795730436020560.3258
2023-12-31Decheng Capital LLC0.95724.64158697908697900
2023-12-31Morgan Stanley - Brokerage Accounts0.77190.00127013959240915.1742
2023-12-31BNP Paribas Investment Partners SA0.5940.0287539727228634.4234
2023-12-31Northern Trust Corp0.57740.001852468972051.3923
2023-12-31Balyasny Asset Management LLC0.56730.01855154535100310.9814
Total 46.397932.059942159327+3120285+7.4%

3.2. Funds holding Arcus Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29iShares Core S&P Small-Cap ETF4.04140.0907367224059400.162
2024-01-31Fidelity Select Biotechnology3.23220.9639293689600
2024-02-29SPDR® S&P Biotech ETF2.60060.57082363021441601.9044
2024-02-29Vanguard Total Stock Mkt Idx Inv1.68210.0019152842500
2024-02-29iShares Russell 2000 ETF1.42670.03981296345-212-0.0164
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.870.014879054759130.7536
2024-01-31Fidelity Select Health Care0.77040.1386700000230893.4109
2024-02-29Vanguard Small Cap Index0.690.008562698957120.9194
2024-01-31AB Discovery Growth A0.62110.3301564381-6467-1.1329
2024-02-29CT American Smaller Coms(US) InstAccGBP0.59450.8499540175269465.2503
2023-12-31Fidelity Small Cap Index0.58950.0403535615166273.2037
2024-02-29SPDR® Portfolio S&P 600 Sm Cap ETF0.54230.0918492769990.0201
2024-01-31Fidelity Advisor Health Care I0.49520.14145000011260.2508
2024-02-29Vanguard Tax-Managed Small Cap Adm0.46340.090642107000
2024-02-29iShares S&P Small-Cap 600 Value ETF0.44270.109440222211070.276
2024-02-29CT (Lux) American Smaller Com 9U USD0.43460.8633394879229836.18
2024-01-31Delaware Healthcare I0.41720.780837910000
2024-02-29iShares Biotechnology ETF0.40840.0933371081-1670-0.448
2024-02-01iShares Russell 2000 Value ETF0.39120.04773554804500.1267
2024-02-29Vanguard Small Cap Growth Index Inv0.38740.019335196858501.6902
Total 21.10095.286519173203+151653+0.8%

3.3. Insider Transactions

Insiders are holding 41.173% of the shares of Arcus Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-27Jennifer JarrettSELL1155117.55
2024-03-18Jennifer JarrettSELL1344917.92
2024-02-26Jennifer JarrettSELL2455520.07
2024-02-26Juan C JaenSELL390020.06
2024-01-29Gilead Sciences, Inc.BUY1523809521
2024-01-02Juan C JaenSELL697520.09
2024-01-02Robert C Goeltz IiSELL200420
2023-12-22Jennifer JarrettSELL2152117.76
2023-09-22Jennifer JarrettSELL2136919.99
2023-07-28Jennifer JarrettSELL4500020.25
2023-07-03Alexander AzoySELL101820.41
2023-06-28Gilead Sciences, Inc.BUY101000019.26
2023-06-22Jennifer JarrettSELL1243719.12
2023-06-16Jennifer JarrettSELL1256319.35

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Arcus Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.638-0.537-16%-0.507-20%0.125-611%0.175-464%
Book Value Per Share--5.0845.910-14%7.978-36%5.545-8%4.413+15%
Current Ratio--4.5165.019-10%6.767-33%6.864-34%8.156-45%
Debt To Asset Ratio--0.5780.550+5%0.497+16%0.366+58%0.291+99%
Debt To Equity Ratio--1.3701.226+12%0.989+39%0.672+104%0.508+170%
Dividend Per Share----0%-0%-0%-0%
Eps---0.891-0.845-5%-0.735-18%-0.401-55%-0.322-64%
Free Cash Flow Per Share---1.035-0.908-12%1.172-188%-0.084-92%-0.094-91%
Free Cash Flow To Equity Per Share---1.001-0.817-18%1.263-179%0.324-409%0.304-429%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---32.202--------
Intrinsic Value_10Y_min---26.975--------
Intrinsic Value_1Y_max---1.053--------
Intrinsic Value_1Y_min---1.033--------
Intrinsic Value_3Y_max---4.820--------
Intrinsic Value_3Y_min---4.568--------
Intrinsic Value_5Y_max---10.585--------
Intrinsic Value_5Y_min---9.682--------
Market Cap1333895264.000-30%1735517680.0001717344720.000+1%2356578588.000-26%1960771519.200-11%1516408181.241+14%
Net Profit Margin---2.613-2.654+2%-50.542+1834%-16.181+519%-17.504+570%
Operating Margin---2.581-2.785+8%-55.717+2059%-17.396+574%-18.482+616%
Operating Ratio--4.0974.073+1%83.616-95%25.454-84%30.435-87%
Pb Ratio2.887-30%3.7573.229+16%3.236+16%4.243-11%3.580+5%
Pe Ratio-4.117+23%-5.357-5.608+5%-8.825+65%2.567-309%-1.568-71%
Price Per Share14.680-30%19.10018.900+1%25.935-26%21.579-11%16.689+14%
Price To Free Cash Flow Ratio-3.548+23%-4.616-5.436+18%-5.183+12%-9.222+100%-9.985+116%
Price To Total Gains Ratio-22.998+23%-29.923-37.184+24%-51.150+71%-36.599+22%-43.426+45%
Quick Ratio--7.7888.908-13%11.447-32%11.390-32%12.216-36%
Return On Assets---0.074-0.065-13%-0.045-39%-0.060-18%-0.068-8%
Return On Equity---0.175-0.144-18%-0.090-49%-0.092-48%-0.093-47%
Total Gains Per Share---0.638-0.537-16%-0.507-20%0.125-611%0.175-464%
Usd Book Value--462000000.000537000000.000-14%724916500.000-36%503820950.000-8%401012241.379+15%
Usd Book Value Change Per Share---0.638-0.537-16%-0.507-20%0.125-611%0.175-464%
Usd Book Value Per Share--5.0845.910-14%7.978-36%5.545-8%4.413+15%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.891-0.845-5%-0.735-18%-0.401-55%-0.322-64%
Usd Free Cash Flow---94000000.000-82500000.000-12%106500000.000-188%-7676050.000-92%-8547448.276-91%
Usd Free Cash Flow Per Share---1.035-0.908-12%1.172-188%-0.084-92%-0.094-91%
Usd Free Cash Flow To Equity Per Share---1.001-0.817-18%1.263-179%0.324-409%0.304-429%
Usd Market Cap1333895264.000-30%1735517680.0001717344720.000+1%2356578588.000-26%1960771519.200-11%1516408181.241+14%
Usd Price Per Share14.680-30%19.10018.900+1%25.935-26%21.579-11%16.689+14%
Usd Profit---81000000.000-76750000.000-5%-64928000.000-20%-36072500.000-55%-29037793.103-64%
Usd Revenue--31000000.00029250000.000+6%19672500.000+58%33554450.000-8%23477758.621+32%
Usd Total Gains Per Share---0.638-0.537-16%-0.507-20%0.125-611%0.175-464%
 EOD+3 -5MRQTTM+7 -26YOY+6 -275Y+7 -2610Y+12 -21

4.2. Fundamental Score

Let's check the fundamental score of Arcus Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.117
Price to Book Ratio (EOD)Between0-12.887
Net Profit Margin (MRQ)Greater than0-2.613
Operating Margin (MRQ)Greater than0-2.581
Quick Ratio (MRQ)Greater than17.788
Current Ratio (MRQ)Greater than14.516
Debt to Asset Ratio (MRQ)Less than10.578
Debt to Equity Ratio (MRQ)Less than11.370
Return on Equity (MRQ)Greater than0.15-0.175
Return on Assets (MRQ)Greater than0.05-0.074
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Arcus Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.488
Ma 20Greater thanMa 5016.742
Ma 50Greater thanMa 10017.474
Ma 100Greater thanMa 20017.083
OpenGreater thanClose14.670
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,095,000
Total Liabilities633,000
Total Stockholder Equity462,000
 As reported
Total Liabilities 633,000
Total Stockholder Equity+ 462,000
Total Assets = 1,095,000

Assets

Total Assets1,095,000
Total Current Assets831,000
Long-term Assets264,000
Total Current Assets
Cash And Cash Equivalents 127,000
Short-term Investments 632,000
Net Receivables 42,000
Other Current Assets 30,000
Total Current Assets  (as reported)831,000
Total Current Assets  (calculated)831,000
+/-0
Long-term Assets
Property Plant Equipment 51,000
Long Term Investments 107,000
Long-term Assets Other 106,000
Long-term Assets  (as reported)264,000
Long-term Assets  (calculated)264,000
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities184,000
Long-term Liabilities449,000
Total Stockholder Equity462,000
Total Current Liabilities
Short-term Debt 11,000
Accounts payable 17,000
Other Current Liabilities 65,000
Total Current Liabilities  (as reported)184,000
Total Current Liabilities  (calculated)93,000
+/- 91,000
Long-term Liabilities
Capital Lease Obligations 11,000
Long-term Liabilities Other 142,000
Long-term Liabilities  (as reported)449,000
Long-term Liabilities  (calculated)153,000
+/- 296,000
Total Stockholder Equity
Common Stock1,311,000
Retained Earnings -849,000
Total Stockholder Equity (as reported)462,000
Total Stockholder Equity (calculated)462,000
+/-0
Other
Capital Stock1,311,000
Cash and Short Term Investments 759,000
Common Stock Shares Outstanding 75,000
Current Deferred Revenue91,000
Liabilities and Stockholders Equity 1,095,000
Net Debt -116,000
Net Invested Capital 462,000
Net Working Capital 647,000
Property Plant and Equipment Gross 82,000
Short Long Term Debt Total 11,000



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
109,702
0
0
0
190,486
305,399
293,865
286,721
274,925
258,530
238,974
216,957
203,110
176,144
481,389
811,075
772,292
935,119
898,773
839,290
1,591,898
1,543,427
1,476,773
1,393,822
1,345,000
1,254,000
1,220,000
1,191,000
1,095,000
1,095,0001,191,0001,220,0001,254,0001,345,0001,393,8221,476,7731,543,4271,591,898839,290898,773935,119772,292811,075481,389176,144203,110216,957238,974258,530274,925286,721293,865305,399190,486000109,702
   > Total Current Assets 
99,691
98,896
0
0
176,869
282,068
267,441
265,280
258,948
245,015
227,733
200,488
192,705
166,217
471,599
797,199
735,086
841,870
745,954
545,288
681,298
1,264,226
1,227,475
1,101,116
1,067,000
1,015,000
986,000
882,000
831,000
831,000882,000986,0001,015,0001,067,0001,101,1161,227,4751,264,226681,298545,288745,954841,870735,086797,199471,599166,217192,705200,488227,733245,015258,948265,280267,441282,068176,8690098,89699,691
       Cash And Cash Equivalents 
65,160
-98,896
0
0
98,426
198,116
169,998
74,889
71,064
68,499
76,068
78,992
57,937
67,326
285,185
221,849
173,415
390,260
320,482
179,432
147,914
548,783
272,629
217,647
206,000
238,000
230,000
184,000
127,000
127,000184,000230,000238,000206,000217,647272,629548,783147,914179,432320,482390,260173,415221,849285,18567,32657,93778,99276,06868,49971,06474,889169,998198,11698,42600-98,89665,160
       Short-term Investments 
33,736
197,792
0
0
77,277
82,064
95,700
182,948
185,480
173,436
148,330
111,997
130,333
90,540
177,288
560,583
555,231
436,666
400,530
345,210
351,394
664,751
900,147
831,135
803,000
716,000
700,000
615,000
632,000
632,000615,000700,000716,000803,000831,135900,147664,751351,394345,210400,530436,666555,231560,583177,28890,540130,333111,997148,330173,436185,480182,94895,70082,06477,27700197,79233,736
       Net Receivables 
405
0
0
0
25
54
193
5,114
83
83
62
5,276
132
344
461
2,951
1,698
6,264
2,975
3,072
746,822
32,165
39,027
30,709
43,000
36,000
37,000
56,000
42,000
42,00056,00037,00036,00043,00030,70939,02732,165746,8223,0722,9756,2641,6982,9514613441325,2766283835,1141935425000405
       Other Current Assets 
390
0
0
0
1,141
1,834
1,550
2,329
2,321
3,080
3,273
4,223
4,303
8,007
8,665
11,816
5,471
8,680
21,967
17,574
15,620
18,527
15,672
21,625
58,000
25,000
19,000
83,000
30,000
30,00083,00019,00025,00058,00021,62515,67218,52715,62017,57421,9678,6805,47111,8168,6658,0074,3034,2233,2733,0802,3212,3291,5501,8341,141000390
   > Long-term Assets 
0
0
0
0
13,617
23,331
26,424
21,441
15,977
13,515
11,241
16,469
10,405
9,927
9,790
13,876
37,206
93,249
152,819
294,002
910,600
279,201
249,298
292,706
278,000
239,000
234,000
309,000
264,000
264,000309,000234,000239,000278,000292,706249,298279,201910,600294,002152,81993,24937,20613,8769,7909,92710,40516,46911,24113,51515,97721,44126,42423,33113,6170000
       Property Plant Equipment 
8,608
0
0
0
11,230
11,813
12,513
11,762
11,107
11,026
10,362
10,011
9,330
8,761
8,264
8,728
23,588
27,092
59,943
64,371
137,423
136,473
137,441
135,965
35,000
37,000
45,000
50,000
51,000
51,00050,00045,00037,00035,000135,965137,441136,473137,42364,37159,94327,09223,5888,7288,2648,7619,33010,01110,36211,02611,10711,76212,51311,81311,2300008,608
       Long Term Investments 
1,000
0
0
0
682
11,110
13,503
9,271
4,383
1,971
357
5,992
0
0
0
2,700
6,440
57,986
84,096
218,730
181,990
128,836
98,329
143,138
129,000
90,000
80,000
151,000
107,000
107,000151,00080,00090,000129,000143,13898,329128,836181,990218,73084,09657,9866,4402,7000005,9923571,9714,3839,27113,50311,1106820001,000
       Long-term Assets Other 
0
0
0
0
1,705
408
408
408
487
518
522
466
1,075
1,166
1,526
2,448
7,178
8,171
8,780
10,901
591,187
13,892
13,528
13,603
114,000
112,000
109,000
108,000
106,000
106,000108,000109,000112,000114,00013,60313,52813,892591,18710,9018,7808,1717,1782,4481,5261,1661,0754665225184874084084081,7050000
> Total Liabilities 
10,242
0
0
0
36,618
38,808
39,291
41,600
39,983
36,963
42,328
39,730
39,268
35,506
52,679
266,658
269,988
270,329
294,218
296,683
750,448
746,848
729,387
695,121
688,000
654,000
654,000
671,000
633,000
633,000671,000654,000654,000688,000695,121729,387746,848750,448296,683294,218270,329269,988266,65852,67935,50639,26839,73042,32836,96339,98341,60039,29138,80836,61800010,242
   > Total Current Liabilities 
5,546
0
0
0
12,726
14,262
16,380
16,611
16,935
19,003
26,513
21,057
22,706
21,004
40,025
162,871
121,669
132,055
130,370
142,866
166,084
161,254
164,024
177,176
193,000
179,000
180,000
200,000
184,000
184,000200,000180,000179,000193,000177,176164,024161,254166,084142,866130,370132,055121,669162,87140,02521,00422,70621,05726,51319,00316,93516,61116,38014,26212,7260005,546
       Short-term Debt 
0
0
0
0
3,137
3,610
4,342
6,667
6,023
7,629
15,552
9,662
9,522
10,170
19,510
35,733
15,243
30,559
38,462
55,095
53,768
0
0
0
3,000
0
57,000
9,000
11,000
11,0009,00057,00003,00000053,76855,09538,46230,55915,24335,73319,51010,1709,5229,66215,5527,6296,0236,6674,3423,6103,1370000
       Accounts payable 
3,867
0
0
0
3,820
3,920
5,388
2,109
3,102
2,829
2,448
2,905
4,704
2,426
12,052
8,102
15,682
24,544
16,957
13,219
10,261
18,094
21,984
10,546
20,000
28,000
12,000
17,000
17,000
17,00017,00012,00028,00020,00010,54621,98418,09410,26113,21916,95724,54415,6828,10212,0522,4264,7042,9052,4482,8293,1022,1095,3883,9203,8200003,867
       Other Current Liabilities 
1,679
0
0
0
769
1,732
1,650
1,585
1,560
1,545
1,513
1,490
1,480
1,408
1,463
3,422
16,173
2,381
380
209
52
53,850
51,923
63,339
73,000
54,000
8,000
71,000
65,000
65,00071,0008,00054,00073,00063,33951,92353,850522093802,38116,1733,4221,4631,4081,4801,4901,5131,5451,5601,5851,6501,7327690001,679
   > Long-term Liabilities 
0
0
0
0
23,892
24,546
22,911
24,989
23,048
17,960
15,815
18,673
16,562
14,502
12,654
103,787
148,319
138,274
163,848
153,817
584,364
585,594
565,363
517,945
495,000
475,000
474,000
471,000
449,000
449,000471,000474,000475,000495,000517,945565,363585,594584,364153,817163,848138,274148,319103,78712,65414,50216,56218,67315,81517,96023,04824,98922,91124,54623,8920000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-3,137
-3,610
-4,342
-6,667
-6,023
-7,629
-15,552
-9,662
-9,522
-10,170
-19,510
-35,733
0
-15,853
11,279
-6,152
63,119
114,815
121,343
119,195
0
0
-57,000
0
0
00-57,00000119,195121,343114,81563,119-6,15211,279-15,8530-35,733-19,510-10,170-9,522-9,662-15,552-7,629-6,023-6,667-4,342-3,610-3,1370000
       Long-term Liabilities Other 
0
0
0
0
0
2,554
2,308
2,047
1,792
1,543
1,283
1,026
806
640
693
99,476
148,319
138,274
10,199
153,817
584,364
585,594
565,363
517,945
140,000
145,000
144,000
145,000
142,000
142,000145,000144,000145,000140,000517,945565,363585,594584,364153,81710,199138,274148,31999,4766936408061,0261,2831,5431,7922,0472,3082,55400000
       Deferred Long Term Liability 
0
0
0
0
1,300
21,992
20,603
22,942
21,256
16,417
14,532
17,647
15,756
3,590
3,439
4,311
3,200
3,100
3,000
2,900
4,000
4,000
3,700
3,400
3,000
3,000
3,000
2,000
0
02,0003,0003,0003,0003,4003,7004,0004,0002,9003,0003,1003,2004,3113,4393,59015,75617,64714,53216,41721,25622,94220,60321,9921,3000000
> Total Stockholder Equity
99,460
99,460
0
0
153,868
266,591
254,574
245,121
234,942
221,567
196,646
177,227
163,842
140,638
428,710
544,417
502,304
664,790
604,555
542,607
841,450
796,579
747,386
698,701
657,000
600,000
566,000
520,000
462,000
462,000520,000566,000600,000657,000698,701747,386796,579841,450542,607604,555664,790502,304544,417428,710140,638163,842177,227196,646221,567234,942245,121254,574266,591153,8680099,46099,460
   Common Stock
1
0
0
0
3
4
4
4
4
4
4
4
4
4
6
6
6
7
7
7
7
7
7
7
1,206,000
1,226,000
1,267,000
1,291,000
1,311,000
1,311,0001,291,0001,267,0001,226,0001,206,000777777766644444444430001
   Retained Earnings Total Equity00-697,000-622,0000-474,898-409,979-343,347-275,354-554,722-476,747-400,777-328,184-276,331-278,153-233,079-205,326-188,728-166,376-138,286-122,828-110,533-99,722-86,18800000
   Accumulated Other Comprehensive Income 
0
0
0
0
-42
-97
-83
-108
-107
29
113
53
64
288
144
81
44
-2
-46
-92
-1,261
-4,660
-7,244
-9,801
-7,000
-4,000
-4,000
-3,000
0
0-3,000-4,000-4,000-7,000-9,801-7,244-4,660-1,261-92-46-24481144288645311329-107-108-83-97-420000
   Capital Surplus 
0
0
0
0
0
352,872
354,375
355,758
357,873
359,820
362,905
365,898
369,100
373,425
706,713
820,661
830,438
1,065,562
1,081,341
1,097,414
1,118,058
1,144,579
1,164,602
1,183,393
0
0
0
0
0
000001,183,3931,164,6021,144,5791,118,0581,097,4141,081,3411,065,562830,438820,661706,713373,425369,100365,898362,905359,820357,873355,758354,375352,87200000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
-26
-19,994
0
0
231,077
47,473
60,510
69,037
365,409
101,290
123,931
148,941
380,385
197,281
706,857
820,661
502,254
1,065,562
1,081,341
1,097,414
1,118,058
1,144,579
1,164,602
1,183,393
-7,000
-4,000
-4,000
-3,000
0
0-3,000-4,000-4,000-7,0001,183,3931,164,6021,144,5791,118,0581,097,4141,081,3411,065,562502,254820,661706,857197,281380,385148,941123,931101,290365,40969,03760,51047,473231,07700-19,994-26



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue117,000
Cost of Revenue-16,000
Gross Profit101,000101,000
 
Operating Income (+$)
Gross Profit101,000
Operating Expense-457,000
Operating Income-340,000-356,000
 
Operating Expense (+$)
Research Development340,000
Selling General Administrative117,000
Selling And Marketing Expenses0
Operating Expense457,000457,000
 
Net Interest Income (+$)
Interest Income41,000
Interest Expense-2,000
Other Finance Cost-0
Net Interest Income39,000
 
Pretax Income (+$)
Operating Income-340,000
Net Interest Income39,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-301,000-379,000
EBIT - interestExpense = -301,000
-301,000
-305,000
Interest Expense2,000
Earnings Before Interest and Taxes (EBIT)-299,000-299,000
Earnings Before Interest and Taxes (EBITDA)-291,000
 
After tax Income (+$)
Income Before Tax-301,000
Tax Provision-6,000
Net Income From Continuing Ops-307,000-307,000
Net Income-307,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses457,000
Total Other Income/Expenses Net39,000-39,000
 

Technical Analysis of Arcus Biosciences Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Arcus Biosciences Inc. The general trend of Arcus Biosciences Inc is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Arcus Biosciences Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Arcus Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 16.10 < 19.11 < 19.98.

The bearish price targets are: 13.50 > 12.95.

Tweet this
Arcus Biosciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Arcus Biosciences Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Arcus Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Arcus Biosciences Inc. The current macd is -0.75923966.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Arcus Biosciences Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Arcus Biosciences Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Arcus Biosciences Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Arcus Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartArcus Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Arcus Biosciences Inc. The current adx is 18.01.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Arcus Biosciences Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Arcus Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Arcus Biosciences Inc. The current sar is 16.78.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Arcus Biosciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Arcus Biosciences Inc. The current rsi is 33.49. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Arcus Biosciences Inc Daily Relative Strength Index (RSI) ChartArcus Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Arcus Biosciences Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Arcus Biosciences Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Arcus Biosciences Inc Daily Stochastic Oscillator ChartArcus Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Arcus Biosciences Inc. The current cci is -142.6763113.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Arcus Biosciences Inc Daily Commodity Channel Index (CCI) ChartArcus Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Arcus Biosciences Inc. The current cmo is -45.6659998.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Arcus Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartArcus Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Arcus Biosciences Inc. The current willr is -85.35353535.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Arcus Biosciences Inc Daily Williams %R ChartArcus Biosciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Arcus Biosciences Inc.

Arcus Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Arcus Biosciences Inc. The current atr is 0.88566306.

Arcus Biosciences Inc Daily Average True Range (ATR) ChartArcus Biosciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Arcus Biosciences Inc. The current obv is -14,880,628.

Arcus Biosciences Inc Daily On-Balance Volume (OBV) ChartArcus Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Arcus Biosciences Inc. The current mfi is 26.88.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Arcus Biosciences Inc Daily Money Flow Index (MFI) ChartArcus Biosciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Arcus Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-01ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Arcus Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Arcus Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.488
Ma 20Greater thanMa 5016.742
Ma 50Greater thanMa 10017.474
Ma 100Greater thanMa 20017.083
OpenGreater thanClose14.670
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Arcus Biosciences Inc with someone you think should read this too:
  • Are you bullish or bearish on Arcus Biosciences Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Arcus Biosciences Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Arcus Biosciences Inc

I send you an email if I find something interesting about Arcus Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Arcus Biosciences Inc.

Receive notifications about Arcus Biosciences Inc in your mailbox!